Vie Ventures

Shared biology.Broader therapeuticopportunity.

Autoimmune and immune-mediated conditions are often linked by shared immune pathways, genetics, biomarkers, and therapeutic mechanisms. A therapy developed for one disease may have relevance in others. Vie follows that biology across traditional disease boundaries, while evaluating each indication and investment on its own merits.

Autoimmune and immune-mediated conditions

Autoimmune and immune-mediated conditions span multiple organs and tissues. Examples include Crohn's disease, celiac disease, lupus, multiple sclerosis, psoriasis, rheumatoid arthritis, scleroderma, Sjögren's disease and type 1 diabetes. Food allergy is an immune-mediated condition, not a classic autoimmune disorder.

Crohn's diseaseCeliac diseaseLupusMultiple sclerosisPsoriasisRheumatoid arthritisSclerodermaSjögren's diseaseType 1 diabetesFood allergy (immune-mediated)

A substantial patient burden

Large patient populations

Autoimmune and immune-mediated disorders affect large patient populations, often impose substantial lifelong burdens, and retain significant unmet medical need.

Diagnosed young, treated for life

Many patients are diagnosed young and require lifelong therapy. Patients oftentimes present in the first half of life and typically experience chronic illness that requires some version of lifelong therapy, resulting in significant cost over the course of that patient's life.

Significant unmet needs remain

While there have been important advances, significant unmet medical needs remain across the breadth of autoimmune and immunological conditions.

The scientific opportunity

Shared biology

Related genetics and immune pathways connect many conditions.

Multi-indication potential

Clinical validation in one setting may inform development in others.

New therapeutic tools

Precision biologics, cell therapies, immune reset and tolerance are expanding options.

Specialist execution

Capital and experienced development teams can help translate discoveries into interpretable human evidence.

A moment of breakthrough

Novel technologies

Novel technologies are enabling breakthrough treatments and the potential for prevention across immune-mediated disease.

Insights across diseases

The immuno-oncology revolution offers insights and tools to address other diseases of the immune system, and innovation can be accelerated by harvesting a deep understanding of the links between autoimmune diseases.

The biology is being decoded

There are growing opportunities to leverage biological insights, develop biomarkers, better select patients for clinical studies, and better design clinical trials across indications.

A field at an inflection point.

We invest in the science and the teams building the next generation of therapies for autoimmune and immune-mediated disease.

Or email us directly at contact@vieventures.com.